Higher concentrations of matrix metalloproteinases in bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome

This study was designed to investigate possible involvement of type IV collagenolytic matrix metalloproteinases (MMPs; 72-kDa type IV collagenase [MMP-2], 92-kDa type IV collagenase [MMP-9]), and the respective specific tissue inhibitors of these MMPs (TIMP-2 and TIMP-1) in the development of adult...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	American journal of respiratory and critical care medicine Ročník 155; číslo 1; s. 43
Hlavní autori:	Torii, K, Iida, K, Miyazaki, Y, Saga, S, Kondoh, Y, Taniguchi, H, Taki, F, Takagi, K, Matsuyama, M, Suzuki, R
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.01.1997
Predmet:	Adult Aged Aged, 80 and over Bronchoalveolar Lavage Fluid - chemistry Collagen - analysis Collagenases - analysis Female Gelatinases - analysis Glycoproteins - analysis Humans Laminin - analysis Male Matrix Metalloproteinase 2 Matrix Metalloproteinase 9 Matrix Metalloproteinase Inhibitors Metalloendopeptidases - analysis Middle Aged Protease Inhibitors - analysis Proteins - analysis Respiratory Distress Syndrome, Adult - enzymology Respiratory Distress Syndrome, Adult - metabolism Tissue Inhibitor of Metalloproteinase-2 Tissue Inhibitor of Metalloproteinases
ISSN:	1073-449X
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	This study was designed to investigate possible involvement of type IV collagenolytic matrix metalloproteinases (MMPs; 72-kDa type IV collagenase [MMP-2], 92-kDa type IV collagenase [MMP-9]), and the respective specific tissue inhibitors of these MMPs (TIMP-2 and TIMP-1) in the development of adult respiratory distress syndrome (ARDS). We determined the concentrations of these enzymes in the bronchoalveolar lavage fluid (BALF) from patients with ARDS using newly developed sensitive one-step sandwich enzyme immunoassay methods. BALF obtained from the 17 patients and eight healthy volunteer control subjects were also used for the analysis of the number of the cellular component. Concentrations of the 7S portion of type IV collagen and laminin in the BALF were measured as markers of basement membrane disruption. In the BALF from the ARDS patients, the concentrations of MMP-2 (66.7 +/- 57.0 ng/ml versus < 7.0 ng/ml for controls, p < 0.01) and MMP-9 (118.0 +/- 309.3 ng/ml versus 9.0 +/- 9.5 ng/ml for controls, p < 0.05), and the specific inhibitor of MMP-9 (TIMP-1) (161.0 +/- 145.0 ng/ml versus < 50 ng/ml for controls, p < 0.01) were significantly higher compared with those for healthy control subjects. In the ARDS patients, the concentrations of MMP-2 correlated both with those of 7S collagen and laminin; MMP-9 with the concentration of 7S collagen and the number of neutrophils. These findings suggest that the increased concentration of collagenolytic MMPs in lung plays a role in the pathogenesis of ARDS.
AbstractList	This study was designed to investigate possible involvement of type IV collagenolytic matrix metalloproteinases (MMPs; 72-kDa type IV collagenase [MMP-2], 92-kDa type IV collagenase [MMP-9]), and the respective specific tissue inhibitors of these MMPs (TIMP-2 and TIMP-1) in the development of adult respiratory distress syndrome (ARDS). We determined the concentrations of these enzymes in the bronchoalveolar lavage fluid (BALF) from patients with ARDS using newly developed sensitive one-step sandwich enzyme immunoassay methods. BALF obtained from the 17 patients and eight healthy volunteer control subjects were also used for the analysis of the number of the cellular component. Concentrations of the 7S portion of type IV collagen and laminin in the BALF were measured as markers of basement membrane disruption. In the BALF from the ARDS patients, the concentrations of MMP-2 (66.7 +/- 57.0 ng/ml versus < 7.0 ng/ml for controls, p < 0.01) and MMP-9 (118.0 +/- 309.3 ng/ml versus 9.0 +/- 9.5 ng/ml for controls, p < 0.05), and the specific inhibitor of MMP-9 (TIMP-1) (161.0 +/- 145.0 ng/ml versus < 50 ng/ml for controls, p < 0.01) were significantly higher compared with those for healthy control subjects. In the ARDS patients, the concentrations of MMP-2 correlated both with those of 7S collagen and laminin; MMP-9 with the concentration of 7S collagen and the number of neutrophils. These findings suggest that the increased concentration of collagenolytic MMPs in lung plays a role in the pathogenesis of ARDS. This study was designed to investigate possible involvement of type IV collagenolytic matrix metalloproteinases (MMPs; 72-kDa type IV collagenase [MMP-2], 92-kDa type IV collagenase [MMP-9]), and the respective specific tissue inhibitors of these MMPs (TIMP-2 and TIMP-1) in the development of adult respiratory distress syndrome (ARDS). We determined the concentrations of these enzymes in the bronchoalveolar lavage fluid (BALF) from patients with ARDS using newly developed sensitive one-step sandwich enzyme immunoassay methods. BALF obtained from the 17 patients and eight healthy volunteer control subjects were also used for the analysis of the number of the cellular component. Concentrations of the 7S portion of type IV collagen and laminin in the BALF were measured as markers of basement membrane disruption. In the BALF from the ARDS patients, the concentrations of MMP-2 (66.7 +/- 57.0 ng/ml versus < 7.0 ng/ml for controls, p < 0.01) and MMP-9 (118.0 +/- 309.3 ng/ml versus 9.0 +/- 9.5 ng/ml for controls, p < 0.05), and the specific inhibitor of MMP-9 (TIMP-1) (161.0 +/- 145.0 ng/ml versus < 50 ng/ml for controls, p < 0.01) were significantly higher compared with those for healthy control subjects. In the ARDS patients, the concentrations of MMP-2 correlated both with those of 7S collagen and laminin; MMP-9 with the concentration of 7S collagen and the number of neutrophils. These findings suggest that the increased concentration of collagenolytic MMPs in lung plays a role in the pathogenesis of ARDS.This study was designed to investigate possible involvement of type IV collagenolytic matrix metalloproteinases (MMPs; 72-kDa type IV collagenase [MMP-2], 92-kDa type IV collagenase [MMP-9]), and the respective specific tissue inhibitors of these MMPs (TIMP-2 and TIMP-1) in the development of adult respiratory distress syndrome (ARDS). We determined the concentrations of these enzymes in the bronchoalveolar lavage fluid (BALF) from patients with ARDS using newly developed sensitive one-step sandwich enzyme immunoassay methods. BALF obtained from the 17 patients and eight healthy volunteer control subjects were also used for the analysis of the number of the cellular component. Concentrations of the 7S portion of type IV collagen and laminin in the BALF were measured as markers of basement membrane disruption. In the BALF from the ARDS patients, the concentrations of MMP-2 (66.7 +/- 57.0 ng/ml versus < 7.0 ng/ml for controls, p < 0.01) and MMP-9 (118.0 +/- 309.3 ng/ml versus 9.0 +/- 9.5 ng/ml for controls, p < 0.05), and the specific inhibitor of MMP-9 (TIMP-1) (161.0 +/- 145.0 ng/ml versus < 50 ng/ml for controls, p < 0.01) were significantly higher compared with those for healthy control subjects. In the ARDS patients, the concentrations of MMP-2 correlated both with those of 7S collagen and laminin; MMP-9 with the concentration of 7S collagen and the number of neutrophils. These findings suggest that the increased concentration of collagenolytic MMPs in lung plays a role in the pathogenesis of ARDS.
Author	Takagi, K Taki, F Matsuyama, M Saga, S Torii, K Miyazaki, Y Iida, K Taniguchi, H Kondoh, Y Suzuki, R
Author_xml	– sequence: 1 givenname: K surname: Torii fullname: Torii, K organization: Department of Internal Medicine II, Faculty of Medicine, University of Nagoya, Japan – sequence: 2 givenname: K surname: Iida fullname: Iida, K – sequence: 3 givenname: Y surname: Miyazaki fullname: Miyazaki, Y – sequence: 4 givenname: S surname: Saga fullname: Saga, S – sequence: 5 givenname: Y surname: Kondoh fullname: Kondoh, Y – sequence: 6 givenname: H surname: Taniguchi fullname: Taniguchi, H – sequence: 7 givenname: F surname: Taki fullname: Taki, F – sequence: 8 givenname: K surname: Takagi fullname: Takagi, K – sequence: 9 givenname: M surname: Matsuyama fullname: Matsuyama, M – sequence: 10 givenname: R surname: Suzuki fullname: Suzuki, R
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/9001287$$D View this record in MEDLINE/PubMed
BookMark	eNotkMFOwzAMhnMYGmPwBiDlxG0jSbOmPaIJGNIkLiBxm9zW3TKlyUjSwZ6A1yZAT5atz5_1-4KMrLNIyDVnc85zeQd7X9fdnC8Wcz4vGeOiUCMy4UxlMynL93NyEcL-b87ZmIwHZEK-V3q7Q09rZ2u00UPUzgbqWtpB9PqLdhjBGHfwLqK2EDBQbWnlE79zYI7oDHhq4AhbpK3pdfO7fEiepAv0U8cdhaY3kXoMB50OOH-ijQ4x9YGGk2286_CSnLVgAl4NdUreHh9el6vZ-uXpeXm_ntVZxuNMllWeAbZQqxJYwUqZS0CRQ96KFK0pJIdKNUJkTOWLUshGqEyxtkhwVolaTMntvzcF-ugxxE2nQ43GgEXXh40qVKkWQibwZgD7qsNmc_C6A3_aDJ8TP9mYdbU
CitedBy_id	crossref_primary_10_1183_09031936_05_00091804 crossref_primary_10_1164_ajrccm_160_4_9811060 crossref_primary_10_1371_journal_pone_0109713 crossref_primary_10_1016_j_cca_2014_03_031 crossref_primary_10_3389_fphar_2022_995051 crossref_primary_10_1053_tvjl_2001_0631 crossref_primary_10_3390_cells11040745 crossref_primary_10_1186_cc8115 crossref_primary_10_1378_chest_124_2_644 crossref_primary_10_1007_s11010_011_1066_0 crossref_primary_10_1165_rcmb_2003_0197OC crossref_primary_10_1161_01_CIR_100_4_400 crossref_primary_10_1006_pupt_2001_0325 crossref_primary_10_1371_journal_pone_0022596 crossref_primary_10_1164_ajrccm_162_5_9906096 crossref_primary_10_1006_jsre_2001_6180 crossref_primary_10_1155_2021_8889313 crossref_primary_10_1007_s12011_011_9180_0 crossref_primary_10_1186_ar4042 crossref_primary_10_1378_chest_14_0397 crossref_primary_10_1016_S0014_2999_01_01209_2 crossref_primary_10_1016_j_athoracsur_2007_07_068 crossref_primary_10_1111_j_1749_6632_1999_tb07752_x crossref_primary_10_1189_jlb_1212623 crossref_primary_10_1016_S0002_9440_10_65625_8 crossref_primary_10_3389_fimmu_2023_1260973 crossref_primary_10_1186_1476_9255_10_29 crossref_primary_10_1097_SHK_0000000000000386 crossref_primary_10_1111_j_2042_3306_2001_tb00590_x crossref_primary_10_1111_j_1365_2249_2005_02840_x crossref_primary_10_1186_1465_9921_6_62 crossref_primary_10_1152_japplphysiol_01164_2004 crossref_primary_10_1186_cc8938 crossref_primary_10_1378_chest_121_5_1478 crossref_primary_10_1152_ajplung_2001_281_2_L387 crossref_primary_10_1191_0267659103pf662oa crossref_primary_10_5966_sctm_2015_0006 crossref_primary_10_1080_01902140490252858 crossref_primary_10_1378_chest_121_4_1269 crossref_primary_10_1038_s41419_020_03320_0 crossref_primary_10_1097_01_shk_0000180619_06317_2c crossref_primary_10_1097_01_fjc_0000242054_66031_5c crossref_primary_10_1046_j_1440_1681_2001_03426_x crossref_primary_10_1016_S1053_2498_01_00250_9 crossref_primary_10_1097_TA_0b013e31802d96cb crossref_primary_10_1016_j_jss_2007_03_083 crossref_primary_10_1097_01_shk_0000245019_63246_31 crossref_primary_10_1097_00000441_199809000_00010 crossref_primary_10_1111_j_1440_1681_2004_04061_x crossref_primary_10_2353_ajpath_2008_070891 crossref_primary_10_1111_j_1440_1843_2008_01233_x crossref_primary_10_1111_j_1530_0277_2007_00352_x crossref_primary_10_1136_bmjresp_2017_000222 crossref_primary_10_1016_j_athoracsur_2010_04_052 crossref_primary_10_1258_ebm_2009_009256 crossref_primary_10_1165_rcmb_2002_0092OC crossref_primary_10_1164_ajrccm_162_5_2001061 crossref_primary_10_1165_ajrcmb_20_4_3405 crossref_primary_10_1016_j_yexmp_2012_03_003 crossref_primary_10_3109_01902140902946962 crossref_primary_10_2165_00003495_200161070_00001 crossref_primary_10_3390_ijms26125448 crossref_primary_10_1002_jcla_21588 crossref_primary_10_1007_s12011_008_8149_0 crossref_primary_10_1007_s00109_014_1121_x crossref_primary_10_1161_01_CIR_100_4_333 crossref_primary_10_1128_IAI_72_8_4393_4400_2004 crossref_primary_10_1080_019021490944232 crossref_primary_10_1164_rccm_200203_258OC crossref_primary_10_1186_rr193 crossref_primary_10_1097_00003246_199902000_00036 crossref_primary_10_1081_JAS_100105868 crossref_primary_10_1016_j_clinbiochem_2006_11_015 crossref_primary_10_1080_10611860600968967 crossref_primary_10_1164_rccm_2109004 crossref_primary_10_1183_13993003_erj_18_5_827 crossref_primary_10_1016_S1164_6756_00_90038_0 crossref_primary_10_1080_135475099230741 crossref_primary_10_1371_journal_pone_0296139 crossref_primary_10_1093_intimm_11_2_217 crossref_primary_10_1186_s12931_014_0150_x crossref_primary_10_1016_S0891_5849_03_00275_2 crossref_primary_10_1097_01_mlg_0000150674_30237_3f crossref_primary_10_1515_cclm_2011_805 crossref_primary_10_1213_01_ANE_0000154307_92060_84 crossref_primary_10_1111_j_1440_1827_2010_02547_x crossref_primary_10_1155_2016_3501373 crossref_primary_10_1016_j_cccn_2004_09_025 crossref_primary_10_1016_j_prrv_2010_03_001 crossref_primary_10_2119_molmed_2010_00138 crossref_primary_10_1007_s00134_005_0043_z crossref_primary_10_1067_mai_2001_119024 crossref_primary_10_1097_MPA_0b013e3181612d19 crossref_primary_10_1165_rcmb_2008_0348TR crossref_primary_10_1164_rccm_201009_1422OC crossref_primary_10_1016_j_rmed_2007_04_019 crossref_primary_10_1371_journal_pone_0094701 crossref_primary_10_1097_PCC_0000000000000431 crossref_primary_10_1189_jlb_0605353 crossref_primary_10_1186_cc6791 crossref_primary_10_1097_00024382_200309000_00014 crossref_primary_10_1016_j_pharmthera_2008_12_002 crossref_primary_10_1164_rccm_201804_0678OC crossref_primary_10_1159_000343304 crossref_primary_10_1097_SHK_0b013e318206f654 crossref_primary_10_1186_s12931_015_0173_y crossref_primary_10_1097_01_CCM_0000048626_02184_F8 crossref_primary_10_1016_S0022_4804_03_00089_1 crossref_primary_10_1186_1465_9921_9_28 crossref_primary_10_1155_2020_6644687 crossref_primary_10_1002_path_1594 crossref_primary_10_1016_j_ejphar_2020_173561 crossref_primary_10_1097_CCM_0b013e3181a5506c crossref_primary_10_1164_ajrccm_160_6_9811084 crossref_primary_10_1016_j_healun_2017_07_014 crossref_primary_10_1038_labinvest_3780406 crossref_primary_10_1046_j_1365_2044_2002_02625_x crossref_primary_10_5858_arpa_2017_0115_SA crossref_primary_10_1016_j_pharmthera_2025_108820
ContentType	Journal Article
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1164/ajrccm.155.1.9001287
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
ExternalDocumentID	9001287
Genre	Journal Article
GroupedDBID	--- -~X .55 .GJ 0R~ 1CY 1KJ 23M 2WC 34G 39C 3O- 3V. 53G 5GY 5RE 7RV 7X7 88E 8AO 8C1 8FI 8FJ 8FW 8R4 8R5 AAEJM AAQQT AAWTL ABJNI ABOCM ABPMR ABUWG ACBNA ACGFO ACGFS ACRZS ADBBV AENEX AFCHL AFFNX AFKRA AFUWQ AHMBA AI. AJJEV ALIPV ALMA_UNASSIGNED_HOLDINGS AN0 BAWUL BENPR BKEYQ BNQBC BPHCQ BVXVI C45 CCPQU CGR CS3 CUY CVF DIK E3Z EBS ECM EIF EJD EMOBN EX3 F5P FRP FYUFA GX1 H13 HMCUK HZ~ IH2 J5H KQ8 L7B M1P M5~ N4W NAPCQ NPM O9- OBH OFXIZ OGEVE OHT OK1 OVD OVIDX P2P PCD PQQKQ PROAC PSQYO Q2X RPM RWL SJN TAE TEORI THO TR2 UKHRP VH1 VXZ W8F WH7 WOQ WOW X7M YCJ YJK ZE2 ZGI ZXP ~02 7X8
ID	FETCH-LOGICAL-c331t-49b63aefac79a0809464ae26a6f2281d841ab7d2230765924d27370f8a083b2c2
IEDL.DBID	7X8
ISICitedReferencesCount	155
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=10_1164_ajrccm_155_1_9001287&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1073-449X
IngestDate	Sun Aug 24 03:52:28 EDT 2025 Wed Feb 19 01:22:54 EST 2025
IsPeerReviewed	true
IsScholarly	true
Issue	1
Language	English
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c331t-49b63aefac79a0809464ae26a6f2281d841ab7d2230765924d27370f8a083b2c2
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
PMID	9001287
PQID	78797524
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_78797524 pubmed_primary_9001287
PublicationCentury	1900
PublicationDate	1997-Jan 19970101
PublicationDateYYYYMMDD	1997-01-01
PublicationDate_xml	– month: 01 year: 1997 text: 1997-Jan
PublicationDecade	1990
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	American journal of respiratory and critical care medicine
PublicationTitleAlternate	Am J Respir Crit Care Med
PublicationYear	1997
SSID	ssj0012810
Score	1.9582359
Snippet	This study was designed to investigate possible involvement of type IV collagenolytic matrix metalloproteinases (MMPs; 72-kDa type IV collagenase [MMP-2],...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	43
SubjectTerms	Adult Aged Aged, 80 and over Bronchoalveolar Lavage Fluid - chemistry Collagen - analysis Collagenases - analysis Female Gelatinases - analysis Glycoproteins - analysis Humans Laminin - analysis Male Matrix Metalloproteinase 2 Matrix Metalloproteinase 9 Matrix Metalloproteinase Inhibitors Metalloendopeptidases - analysis Middle Aged Protease Inhibitors - analysis Proteins - analysis Respiratory Distress Syndrome, Adult - enzymology Respiratory Distress Syndrome, Adult - metabolism Tissue Inhibitor of Metalloproteinase-2 Tissue Inhibitor of Metalloproteinases
Title	Higher concentrations of matrix metalloproteinases in bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome
URI	https://www.ncbi.nlm.nih.gov/pubmed/9001287 https://www.proquest.com/docview/78797524
Volume	155
WOSCitedRecordID	wos10_1164_ajrccm_155_1_9001287&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwELYKRYiFd0V5emB129huHEtICCEqllYdQMpWOX6IoDYpSVvxD_jb2IkjJsTAkuksReez_fk-33cA3CYyZIYKhiwaHiKaMI0EpQQxLI0ZEBMkXFXNJthkEsUxn7bAXVML455VNntitVGrXLoced8GFmdDTO-XH8j1jHLcqm-gsQXaxAIZF9Ms_uEQcOS1CBhBlPLYF87Z-0FfvBdSLnr2LO0FPV7Zst8hZnXUjA7-95OHYN9DTPhQx8QRaOnsGOyOPYl-Ar7qtx1QuorFzMvmljA3cOH0-j_hQq8cHV9JOKSZPeZKmGYwKaz9Wy7mG-2uw3AuNnYvgma-TpUb7BVaS-hSu7DS9YDFD5EPVVrXpcBGJOEUvI6eXh6fke_HgCQhwQpRnoREaCMk48IiTU5DKjQORWiwdbaKaCASprB7W-7YWqosNmIDE1ljkmCJO2A7yzN9BqAMFGFc6UiLgGJNhFGBsdBHcKaEZqwLbhoHz2y8OxJDZDpfl7PGxV3QqedotqxlOWZ-Hs__HHoB9moRWpdIuQRtYxe6vgI7crNKy-K6iiL7nUzH3x_O1qs
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Higher+concentrations+of+matrix+metalloproteinases+in+bronchoalveolar+lavage+fluid+of+patients+with+adult+respiratory+distress+syndrome&rft.jtitle=American+journal+of+respiratory+and+critical+care+medicine&rft.au=Torii%2C+K&rft.au=Iida%2C+K&rft.au=Miyazaki%2C+Y&rft.au=Saga%2C+S&rft.date=1997-01-01&rft.issn=1073-449X&rft.volume=155&rft.issue=1&rft.spage=43&rft_id=info:doi/10.1164%2Fajrccm.155.1.9001287&rft_id=info%3Apmid%2F9001287&rft_id=info%3Apmid%2F9001287&rft.externalDocID=9001287
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1073-449X&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1073-449X&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1073-449X&client=summon